NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

NovoCure Ltd

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026

$14.89+0.82 (+5.83%)

Close on Oct 19, 2026

Market cap: $1.73B
P/E (TTM): –
Dividend yield: –

NovoCure Ltd income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	655	605	509	538	535	494	351	248	177	83	33	15	10
Cost of Revenue	167	137	128	115	115	107	89	80	56	40	21	10	7.01
Gross Profit	488	468	381	423	420	388	263	168	121	37	12	5.45	3.35
Research & Development	225	210	223	206	201	132	79	51	38	41	44	40	35
Selling, General & Admin	418	429	391	306	263	225	185	151	123	110	73	45	33
Selling & Marketing	240	239	227	174	137	118	97	78	64	59	39	21	16
General & Administrative	178	190	164	133	126	107	88	73	59	51	34	24	17
Operating Expenses	642	639	614	512	464	357	264	202	161	152	116	86	68
Operating Income	-154	-170	-233	-90	-44	30	-0.91	-34	-39	-115	-104	-80	-64
Interest Expense	22	12	4.91	8.11	8.84	18	15	17	12	7.32	3.24	0.29	13
Interest & Investment Income	13	23	20	11	0.79	1.79	4.40	2.65	1.12	0.66	0.08	0.14	0.27
Merger & Restructuring Charges	0	2.00	6.23	0	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	4.85	1.16	0.49	0.96	0.65	0.43	0.40	0.41	0.24	6.45	0.05	0.02	0.02
Pretax Income	-136	-131	-192	-82	-52	18	-8.82	-46	-48	-121	-107	-80	-77
Income Tax Expense	-0.02	37	15	11	6.28	-1.71	-1.59	18	13	10	4.43	0.38	0.35
Net Income	-136	-169	-207	-93	-58	20	-7.23	-64	-62	-132	-112	-81	-77
Net Income to Common	-136	-169	-207	-93	-58	20	-7.23	-64	–	–	–	–	–
EPS (Basic)(per share)	-1.22	-1.56	-1.95	-0.88	-0.56	0.20	-0.07	-0.69	-0.70	-1.54	-3.67	-6.46	-6.73
EPS (Diluted)(per share)	-1.22	-1.56	-1.95	-0.88	-0.56	0.18	-0.07	-0.69	-0.70	-1.54	-3.67	-6.46	-6.73
Shares Outstanding (Basic, Weighted)(shares)	111	108	106	105	103	101	97	92	89	86	30	12	11
Shares Outstanding (Diluted, Weighted)(shares)	111	108	106	105	103	109	97	92	89	86	30	12	11
EBITDA	-139	-159	-222	-79	-34	40	7.55	-25	-32	-110	-101	-78	-63
Net Interest Income	–	–	–	7.68	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 76.1%
Operating margin: -22.1%
Net margin: -21.2%
Return on equity, FY2025: -38.9%

Financial strength

Current ratio: 2.89
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 42.5%

Valuation

P/E ratio: –
Price to sales: 2.47
Price to book: 5.11
Dividend yield: –